@FierceMedDev: ICYMI: Will Medtronic deal with Covidien benefit smaller players? $MDT exec says yes. Article | Follow @FierceMedDev
@StacyALawrence: ICYMI: FDA clears first robotic exoskeleton for spinal cord injury patients. More | Follow @StacyALawrence
@VarunSaxena2: ICYM last week's feature: Top 10 Med Tech R&D Budgets. Special Report | Follow @VarunSaxena2
@MichaelGFierce: Intersect ENT files for $80M IPO to support steroid-delivering sinus implants. FierceDrugDelivery story | Follow @MichaelGFierce
@EmilyWFierce: FDA OKs first wearable motorized device that helps people with spinal cord injuries walk, More from the NYT | Follow @EmilyWFierce
> Insulet ($PODD) said it agreed to settle a 2010 patent infringement lawsuit filed by Becton Dickinson ($BDX) for $5 million. Story
> The ClearSight system, an Edwards Lifesciences ($EW) noninvasive monitor that provides blood volume and blood flow information on moderate- to high-risk patients on whom invasive monitoring should not be used, was cleared by the FDA. Story
> The FDA expressed concern over companies selling genetic profiles to consumers due to risks of inaccurate results and explained its crackdown on 23andMe. Blog
Biotech News
@FierceBiotech: ICYMI Friday: Another Pfizer bid for AstraZeneca? Investors weigh in. Report | Follow @FierceBiotech
@JohnCFierce: So here's Jeff Stein's new company, Cidara--why all the hush-hush? Release | Follow @JohnCFierce
@DamianFierce: Fun with the U.K. takeover code: $ABBV's $46B bid is blocking $SHPG from shopping for itself. More | Follow @DamianFierce
@EmilyMFierce: Will Europe map the human brain faster than the U.S. can? More from Bloomberg | Follow @EmilyMFierce
> Merck takes to Europe with its promising PD-1 cancer drug. Item
> Two more biotechs roll the IPO dice as the market sputters. More
> Biotech vets sign up to launch Cidara with $32M, new drugs for fungal infections. News
Pharma News
@FiercePharma: Top-read on FP this weekend: Sanofi's Lantus empire imperiled as EU recommends Lilly, Boehringer biosimilar. Article | Follow @FiercePharma
@TracyStaton: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton
@EricPFierce: This Indian pharma exec understands how to attain quality production & that many of his compatriots do not. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: ICYMI: Vertex could snag 250 more Kalydeco patients with EMA nod. Item | Follow @CarlyHFierce
> Wanted: Marketing strategy for MannKind's long-time-coming inhaled insulin. More
> Sex, bribes and videotape: Clandestine video of GSK exec adds to China scandal. Report
> Shire CEO's buyout plans thwarted when AbbVie came calling. Article
CRO News
> Recipharm and CTC unite for early-stage trials. Item
> Evotec pockets a payment in its Boehringer partnership. News
> ClinicalRM teams up with an Ohio network for clinical trials. More
> Bristol-Myers enlists Duke's CRO to help it share trial data. Report
> Parexel expects to hit the $2B mark in fiscal 2015. Article
> Covance is creating an OkCupid for molecules. Story
Biotech IT News
> Survey: Firms prioritizing data security over business-boosting analysis. Story
> U.K. scales back plans for patient database as docs back major revision. Report
> NIH aiming to lower IT barriers to 3D printing in drug research. More
> Experts warn FDA Twitter guidance will silence social conversation. Item
> Bristol-Myers strikes deal with Duke to open up trial data. Story
> Europe's brain project plans grant incentives to encourage data sharing. Article